Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2016 Jun 24. pii: S0167-8140(16)31117-3. doi: 10.1016/j.radonc.2016.05.014
    Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer.
    Tanderup K1,  Fokdal LU2,  Sturdza A3,  Haie-Meder C4,  Mazeron R5,  van Limbergen E6,  Jürgenliemk-Schulz I7,  Petric P8,  Hoskin P9,  Dörr W10,  Bentzen SM11,  Kirisits C12,  Lindegaard JC13,  Pötter R14
    Author information
    1Department of Oncology, Aarhus University Hospital, Denmark. Electronic address: karitand@rm.dk.
    2Department of Oncology, Aarhus University Hospital, Denmark.
    3Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria.
    4Radiation Oncology Department, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France.
    5Radiation Oncology Department, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France.
    6Department of Radiation-Oncology, University Hospitals of Leuven, Belgium.
    7Department of Radiotherapy, University Medical Center Utrecht, The Netherlands.
    8Department of Radiation Oncology, National Center for Cancer Care and Research, Doha, Qatar; Division of Radiotherapy, National Institute of Oncology, Ljubljana, Slovenia.
    9Mount Vernon Cancer Centre, Northwood, United Kingdom.
    10Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria.
    11Greenebaum Cancer Center and Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, USA.
    12Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria.
    13Department of Oncology, Aarhus University Hospital, Denmark.
    14Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria.
    Abstract

    BACKGROUND AND PURPOSE: Currently, there is no consensus on dose prescription in image guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer. The purpose of this study was to provide evidence based recommendations for tumor dose prescription based on results from a multi-center patient series (retroEMBRACE).

    MATERIALS AND METHODS: This study analyzed 488 locally advanced cervical cancer patients treated with external beam radiotherapy±chemotherapy combined with IGABT. Brachytherapy contouring and reporting was according to ICRU/GEC-ESTRO recommendations. The Cox Proportional Hazards model was applied to analyze the effect on local control of dose-volume metrics as well as overall treatment time (OTT), dose rate, chemotherapy, and tumor histology.

    RESULTS: With a median follow up of 46months, 43 local failures were observed. Dose (D90) to the High Risk Clinical Target Volume (CTVHR) (p=0.022, HR=0.967 per Gy) was significant for local control, whereas increasing CTVHR volume (p=0.004, HR=1.017 per cm(3)), and longer OTT (p=0.004, HR=1.023 per day) were associated with worse local control. Histology (p=0.084), chemotherapy (p=0.49) and dose rate (p=1.00) did not have significant impact on local control. Separate analyses according to stage of disease showed that dose to CTVHR, residual gross tumor volume (GTVres), and Intermediate Risk CTV (CTVIR) has significant impact on local control.

    CONCLUSION: CTVHR dose of ⩾85Gy (D90) delivered in 7weeks provides 3-year local control rates of >94% in limited size CTVHR (20cm(3)), >93% in intermediate size (30cm(3)) and >86% in large size (70cm(3)) CTVHR. CTVIR and GTVres dose of ⩾60Gy and ⩾95Gy (D98) leads to similar local control. A dose of 5Gy (CTVHR) is required to compensate an increase of OTT by one week. Increased CTVHR volume by 10cm(3) requires additional 5Gy for equivalent local control.


    Copyright © 2016. Published by Elsevier Ireland Ltd.

    KEYWORDS: Cervical cancer, Dose effect, Image guided brachytherapy, Local control, Overall treatment time

    Publikations ID: 27350396
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt